Published in Int J Mol Sci on June 25, 2012
Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget (2013) 1.05
Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer (2015) 1.05
Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells. Int J Mol Sci (2012) 0.90
Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin. Neoplasia (2013) 0.86
Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative. Oncotarget (2015) 0.78
The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget (2016) 0.76
Two-stage nanoparticle delivery of piperlongumine and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) anti-cancer therapy. Technology (Singap World Sci) (2016) 0.75
Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer. Sci Rep (2016) 0.75
New withanolides with TRAIL-sensitizing effect from Physalis pubescens L. RSC Adv (2016) 0.75
Death receptors: signaling and modulation. Science (1998) 16.95
Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell (1997) 12.83
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 8.69
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
ER stress and the unfolded protein response. Mutat Res (2005) 6.43
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J (2002) 2.91
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev (2003) 2.84
Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature (2010) 2.78
The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem (2002) 2.75
Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity (2004) 2.36
Survivin and molecular pathogenesis of colorectal cancer. Lancet (2003) 2.25
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem (2004) 1.59
Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology (2011) 1.55
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2000) 1.47
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther (2005) 1.43
Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. Cancer Res (2009) 1.43
Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther (2007) 1.41
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene (2003) 1.39
Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res (2001) 1.38
5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol Cancer Ther (2007) 1.35
The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs (2008) 1.31
Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther (2007) 1.30
Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res (2008) 1.25
Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C. Cancer Res (2003) 1.24
Retracted Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem (2010) 1.24
Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene (2004) 1.21
The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther (2006) 1.20
OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res (2008) 1.20
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene (2004) 1.19
Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res (2002) 1.18
Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. World J Hepatol (2011) 1.17
Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutr Cancer (2003) 1.14
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat (2005) 1.13
Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene (2003) 1.12
Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res (1999) 1.12
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res (1998) 1.11
Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther (2010) 1.10
Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res (2007) 1.10
ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2. Apoptosis (2012) 1.09
Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat (2008) 1.07
Retracted Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors, p53, and Bax. J Biol Chem (2010) 1.07
X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin Cancer Res (2005) 1.07
Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res (2001) 1.03
Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene (2001) 1.01
The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther (2000) 1.01
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med (2011) 0.99
Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun (2008) 0.97
Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther (2010) 0.96
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene (2008) 0.96
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol (2005) 0.96
Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int J Oncol (2007) 0.95
ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res (2010) 0.95
Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ (2010) 0.95
TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm (2004) 0.95
Natural products and their role in cancer therapy. Med Oncol (2010) 0.92
Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells. Apoptosis (2011) 0.91
A rice bran polyphenol, cycloartenyl ferulate, elicits apoptosis in human colorectal adenocarcinoma SW480 and sensitizes metastatic SW620 cells to TRAIL-induced apoptosis. Biochem Pharmacol (2009) 0.90
15-deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol Cancer Ther (2008) 0.90
A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX. EMBO J (2012) 0.89
Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. Br J Pharmacol (2011) 0.89
Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett (2010) 0.89
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett (2011) 0.88
Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism. Biochem Biophys Res Commun (2009) 0.87
Combination of isoliquiritigenin and tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in colon cancer HT29 cells. Environ Health Prev Med (2008) 0.86
Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo. Cancer Lett (2010) 0.86
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene (2002) 0.86
Halocynthiaxanthin and peridinin sensitize colon cancer cell lines to tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Res (2007) 0.86
Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins. Br J Pharmacol (2012) 0.84
Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett (2009) 0.83
Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine. Gastroenterology (2009) 0.82
Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo. Cancer Lett (2011) 0.81
2-methoxy-5-amino-N-hydroxybenzamide sensitizes colon cancer cells to TRAIL-induced apoptosis by regulating death receptor 5 and survivin expression. Mol Cancer Ther (2011) 0.81
Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol (2010) 0.80
Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene (2008) 0.80
TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death. Cancer Lett (2005) 0.78
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
Regulation of homeostasis and inflammation in the intestine. Gastroenterology (2011) 1.82
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol (2010) 1.66
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem (2003) 1.54
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol (2008) 1.53
Small bowel capsule endoscopy vs conventional techniques in patients with symptoms highly compatible with Crohn's disease. J Crohns Colitis (2011) 1.52
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol (2007) 1.49
Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc (2006) 1.46
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets (2008) 1.43
"In vitro" azathioprine-induced changes in peripheral T cell apoptosis and IFN-γ production associate with drug response in patients with Crohn's Disease. J Crohns Colitis (2012) 1.40
Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol (2010) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol (2008) 1.35
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol (2008) 1.33
Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol (2004) 1.32
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood (2008) 1.25
Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology (2007) 1.19
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology (2009) 1.19
Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis (2009) 1.18
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology (2006) 1.17
Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol (2011) 1.16
New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.15
Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. Inflamm Bowel Dis (2007) 1.15
Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology (2007) 1.14
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology (2005) 1.14
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther (2012) 1.13
The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway. Proc Natl Acad Sci U S A (2008) 1.12
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol (2006) 1.11
Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm (2009) 1.10
Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology (2002) 1.09
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol (2007) 1.08
The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol (2012) 1.07
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol (2007) 1.06
Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol (2006) 1.06
Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol (2011) 1.04
Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol (2006) 1.04
Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med (2011) 1.03
Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev (2009) 1.03
Aryl hydrocarbon receptor and colitis. Semin Immunopathol (2013) 1.02
Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. Gastroenterology (2004) 1.02
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci (2009) 1.00
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol (2007) 0.99
Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood (2009) 0.99
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol (2009) 0.98
Extracellular signal-regulated protein kinase mediates interleukin 17 (IL-17)-induced IL-8 secretion in Helicobacter pylori-infected human gastric epithelial cells. Infect Immun (2004) 0.98
Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol (2010) 0.98
Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev (2010) 0.98
IL-21 promotes skin recruitment of CD4(+) cells and drives IFN-γ-dependent epidermal hyperplasia. J Immunol (2011) 0.95
Distinct profiles of effector cytokines mark the different phases of Crohn's disease. PLoS One (2013) 0.94
Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res (2011) 0.93
Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. World J Gastroenterol (2010) 0.92
Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflamm Bowel Dis (2011) 0.92